At the news
? BULLISHIMPACT 5/10 6-K filed Jul 15, 2026 at 08:30 ET
Alpha Tau announced the successful treatment of the first patient in its ADMIRE study, evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC). The study targets a high-need population with limited treatment options and builds on momentum from the recently completed ReSTART pivotal trial. This is an early clinical milestone with no efficacy data reported.
- First patient treated in ADMIRE study at Banner MD Anderson Cancer Center
- ADMIRE is a prospective, single-arm study enrolling up to 28 immunocompromised patients with recurrent cSCC
- Primary endpoint: objective response rate (ORR) per RECIST v1.1; secondary endpoints include PFS, OS, and local control over 12 months
- ReSTART pivotal trial for recurrent cSCC recently completed patient enrollment
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access